Taken together, our findings show that VEGFA accelerates GC oncogenesis and progression via the MAPK-AKT/PTEN/TGFβ signaling pathways, and VEGFA has potential to be evaluated as a diagnostic marker for GC diagnosis and target for GC chemotherapy. Here, AKT1 is linked to gastric cancer.